Larimar Therapeutics Investor Relations Material
Latest events
Status Update
Larimar Therapeutics
Access the full event backlog
Slides, Transcripts, and Reports from 13,000 public companies
Latest reports from Larimar Therapeutics Inc
Access all reports
Larimar Therapeutics, Inc. is a clinical-stage biotechnology company dedicated to developing treatments for complex rare diseases. The company's primary focus is on its lead compound, CTI-1601, which is currently being developed as a potential treatment for Friedreich's ataxia, a genetic disorder that affects the nervous system and movement. Larimar leverages its proprietary intracellular delivery platform to design fusion proteins aimed at addressing other rare diseases characterized by deficiencies in intracellular bioactive compounds. The company is headquartered in Bala Cynwyd, Pennsylvania, and its shares are listed on the Nasdaq.
Key slides for Larimar Therapeutics Inc
Study Update
Larimar Therapeutics Inc
Study Update
Larimar Therapeutics Inc
Latest articles
)
Stephen J. Squeri: American Express Veteran Chairman and CEO
Stephen Squeri has spent over four decades at American Express, rising through the ranks to lead one of the world's most recognized brands.
15 Sep 2025
)
Where to? The Story of Uber
Uber's journey from rule-breaking disruptor to disciplined dual-app giant, now shaping the future of mobility, delivery, and autonomy.
5 Sep 2025
)
The Dilemma That Brought Down Kodak
Kodak helped invent digital photography but failed to embrace it. How the innovator's dilemma turned an icon into its own most famous casualty.
21 Aug 2025
Ticker symbol
LRMR
Country
🇺🇸 United States